PT  - JOURNAL ARTICLE
AU  - Zhong, Qing
AU  - Sun, Rui
AU  - Aref, Adel T
AU  - Noor, Zainab
AU  - Anees, Asim
AU  - Zhu, Yi
AU  - Lucas, Natasha
AU  - Poulos, Rebecca C
AU  - Lyu, Mengge
AU  - Zhu, Tiansheng
AU  - Chen, Guo-Bo
AU  - Wang, Yingrui
AU  - Ding, Xuan
AU  - Rutishauser, Dorothea
AU  - Rupp, Niels J
AU  - Rueschoff, Jan H
AU  - Poyet, Cédric
AU  - Hermanns, Thomas
AU  - Fankhauser, Christian
AU  - Rodríguez Martínez, María
AU  - Shao, Wenguang
AU  - Buljan, Marija
AU  - Neumann, Janis Frederick
AU  - Beyer, Andreas
AU  - Hains, Peter G
AU  - Reddel, Roger R
AU  - Robinson, Phillip J
AU  - Aebersold, Ruedi
AU  - Guo, Tiannan
AU  - Wild, Peter J
TI  - Proteomic-based stratification of intermediate-risk prostate cancer patients
AID  - 10.26508/lsa.202302146
DP  - 2024 Feb 01
TA  - Life Science Alliance
PG  - e202302146
VI  - 7
IP  - 2
4099  - https://www.life-science-alliance.org/content/7/2/e202302146.short
4100  - https://www.life-science-alliance.org/content/7/2/e202302146.full
SO  - Life Sci. Alliance2024 Feb 01; 7
AB  - Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B, and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomize prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.